Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects With Treatment-Resistant Depression

To see complete record on, please visit this link

Id: NCT03312894

Organisation Name: Takeda

Overal Status: Withdrawn

Start Date: February 15, 2018

Last Update: February 22, 2018

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Brief Summary: The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.

  • Treatment-Resistant Depression

Total execution time in seconds: 0.24442315101624